1314746-84-3

Upstream product

• 1314747-02-8 3-(8-chloro-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-yl)phenol 
• 75-36-5 acetyl chloride 
• 5000-65-7 2-bromo-3'-methoxyacetophenone 
• 79456-26-1 2-amino-3-chloro-5-(trifluoromethyl)pyridine 
• 38396-89-3 2-bromo-3-acetyloxylacetophenone 
• 2454-35-5 3-acetylphenyl acetate 
• 121-71-1 3-Hydroxyacetophenone 

Downstream Products

• 1314747-02-8 3-(8-chloro-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-yl)phenol 
• 1477503-60-8 1-(3-(8-chloro-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)phenoxy)propan-2-one 
• 1477503-61-9 3-(8-chloro-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)phenyl methanesulfonate 
• 1477503-62-0 3-(8-chloro-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)phenyl 4-methylbenzenesulfonate 

Relevant academic research and scientific papers

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists

In this study, a series of fused-heterocyclic derivatives were systematically designed and synthesized using an efficient route, and evaluated in terms of GLP-1R agonist activity. We employed short synthetic steps and reactions that are tolerant of the presence of various functional groups and suitable for parallel operations to enable the rapid generation of libraries of diverse and structurally complex small molecules. Of the compounds synthesized, 3-(8-chloro-6-(trifluoromethyl)imidazo[1,2-a] pyridin-2-yl)phenyl methanesulfonate (8e) was the most potent agonist with an EC50 of 7.89 μM, and thus is the compound with the greatest potential for application. These findings represent a valuable starting point for the design and discovery of small-molecule GLP-1R agonists that can be administered orally.

A Novel 3-(8-Chloro-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-yl)phenyl acetate skeleton and pharmacophore model as glucagon-like peptide 1 receptor agonists

We screened 10,000 heterocyclic small molecules and identified a novel hit core skeleton of 3-(8-chloro-6-(trifluoromethyl) imidazo[1,2-a]pyridine-2-yl) phenyl acetate derivatives. It has been selected as a potential glucagon-like peptide 1 receptor (GLP-